{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:50:49Z","timestamp":1762271449198},"reference-count":25,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The potency of rabies vaccines, determined using the NIH mouse protection test, can be directly correlated to the amount of rabies virus glycoprotein (RV GP) present in the vaccine. In an effort to develop a simple and sensitive enzyme-linked immunosorbent assay (ELISA) using recombinant diabody for quantification of RV GP, the variable heavy (V\n            <jats:sub>H<\/jats:sub>\n            ) and light chain (V\n            <jats:sub>L<\/jats:sub>\n            ) domains of an RV GP-specific human monoclonal antibody (MAb) secreted by a human \u00d7 mouse heterohybridoma (human MAb R16E5) was amplified, linked using splicing by overlap extension PCR (SOE PCR), and expressed as a recombinant diabody (D06) in the pET28a bacterial expression system. The diabody D06 was purified by immobilized metal affinity chromatography on a nickel-nitrilotriacetic acid (NTA) agarose column and characterized. The purified diabody was used in combination with a well-characterized RV GP-specific mouse MAb, M5B4, to develop an immunocapture ELISA (IC-ELISA) for the quantification of RV GP in human rabies vaccine preparations. The maximum detection limit of the IC-ELISA using the M5B4-D06 combination was up to 31.25 ng\/ml of RV GP. The specificity of the diabody was established by its nonreactivity toward other human viral antigens as determined by ELISA and toward RV GP as determined by immunoblot transfer assay and competitive ELISA with the parent human MAb R16E5 and MAb M5B4. The adjusted\n            <jats:italic>r<\/jats:italic>\n            <jats:sup>2<\/jats:sup>\n            value obtained by the regression through the origin model was 0.902, and the equation for predicted potency values for M5B4-D06-based IC-ELISA and MAb M5B4 IC-ELISA were 0.5651\n            <jats:italic>x<\/jats:italic>\n            and 0.8044\n            <jats:italic>x<\/jats:italic>\n            , respectively, where\n            <jats:italic>x<\/jats:italic>\n            is the estimate of RV GP from the IC-ELISA in micrograms. Analysis of variance (ANOVA) results showed the estimates of the two methods differed significantly (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001), while the predicted potencies by the two tests did not differ significantly (\n            <jats:italic>P<\/jats:italic>\n            &gt; 0.05). The IC-ELISA can be readily adapted to measure the RV GP content in purified antigen, and a vaccine can be formulated based on the estimated GP.\n          <\/jats:p>","DOI":"10.1128\/cvi.00204-10","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T02:41:17Z","timestamp":1277347277000},"page":"1261-1268","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Recombinant Diabody-Based Immunocapture Enzyme-Linked Immunosorbent Assay for Quantification of Rabies Virus Glycoprotein"],"prefix":"10.1128","volume":"17","author":[{"given":"Sridevi V.","family":"Nimmagadda","sequence":"first","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukra M.","family":"Aavula","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelakantam","family":"Biradhar","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varaprasada Sankarasetty","family":"Rao","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajalakshmi","family":"Shanmugham","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dev","family":"Chandran","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagarajan","family":"Thirumeni","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagendrakumar Balasubramanian","family":"Singanallur","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasan Alwar","family":"Villuppanoor","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/protein\/8.7.725","volume":"8","year":"1995","unstructured":"Alfthan, K., K. Takkinen, D. Sizmann, H. S\u00f6derlund, and T. T. Teeri. 1995. Properties of a single-chain antibody containing different linker peptides. Protein Eng.8(7):725-731.","journal-title":"Protein Eng."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0092-1157(89)90018-8","volume":"17","year":"1989","unstructured":"Blancou, J., M. F. Aubert, E. Cain, M. Selve, O. Thraenhart, and L. Bruckner. 1989. Effect of strain differences on the potency testing of rabies vaccines in mice. J. Biol. Stand.17:259-266.","journal-title":"J. Biol. Stand."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1708-8305.2006.00095.x","volume":"14","year":"2007","unstructured":"Bronnert, J., H. Wilde, V. Tepsumethanon, B. Lumlertdacha, and T. Hemachudha. 2007. Organ transplantations and rabies transmission. J. Travel Med.14:177-180.","journal-title":"J. Travel Med."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.11.6714-6720.1992"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2307\/4591470","volume":"77","year":"1962","unstructured":"Constantine, D. L. 1962. Rabies transmission by the non-bite route. Public Health Rep.77:287-289.","journal-title":"Public Health Rep."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3201\/eid1212.060429","volume":"12","year":"2006","unstructured":"Favoretto, S. R., C. C. de Mattos, N. B. de Morais, M. L. Carrieri, B. N. Rolim, L. M. Silva, C. E. Rupprecht, E. L. Durigon, and C. A. de Mattos. 2006. Rabies virus maintained by dogs in humans and terrestrial wildlife, Ceara State, Brazil. Emerg. Infect. Dis.12:1978-1981.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1045-1056(05)80062-4","volume":"20","year":"1992","unstructured":"Ferguson, M., and A. Heath. 1992. Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use. Biologicals20:143-154.","journal-title":"Biologicals"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1045-1056(02)00070-2","volume":"31","year":"2003","unstructured":"Fournier-Caruana, J., B. Poirier, G. Haond, C. Jallet, F. Fuchs, N. Tordo, and P. Perrin. 2003. Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals31(1):9-16.","journal-title":"Biologicals"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1996.0012","volume":"24","year":"1996","unstructured":"Gamoh, K., M. Senda, O. Itoh, M. Muramatsu, N. Hirayama, R. Koike, Y. S. Endoh, and N. Minamoto. 1996. Use of ELISA for in vitro potency test of rabies vaccines for animal use. Biologicals24(2):95-101.","journal-title":"Biologicals"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","volume":"90","year":"1993","unstructured":"Holliger, P., T. Prospero, and G. Winter. 1993. Diabodies: small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U. S. A.90(14):6444-6448.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_12_2","first-page":"360","volume":"83","year":"2005","unstructured":"Knobel, D. L., S. Cleaveland, P. G. Coleman, E. M. F\u00e8vre, M. I. Meltzer, M. E. Miranda, A. Shaw, J. Zinsstag, and F. X. Meslin. 2005. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ.83:360-368.","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-1157(85)80042-1","volume":"13","year":"1985","unstructured":"Lafon, M., P. Perrin, P. Versmisse, and P. Sureau. 1985. Use of a monoclonal antibody for quantification of rabies vaccine glycoprotein by enzyme immunoassay. J. Biol. Stand.13:295-301.","journal-title":"J. Biol. Stand."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0968-0004(93)90034-K","volume":"18","year":"1993","unstructured":"Lindbladh, C., K. Mosbach, and L. B\u00fclow. 1993. Use of genetically prepared enzyme conjugates in enzyme immunoassay. Trends Biochem. Sci.18(8):279-283.","journal-title":"Trends Biochem. Sci."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0022-2836(91)90498-U","volume":"222","year":"1991","unstructured":"Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter. 1991. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol.222:581-597.","journal-title":"J. Mol. Biol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","volume":"348","year":"1990","unstructured":"McCafferty, J., A. D. Griffiths, G. Winter, and D. J. Chiswell. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature348:552-554.","journal-title":"Nature"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jviromet.2007.07.015","volume":"146","year":"2007","unstructured":"Mousli, M., I. Turki, H. Kharmachi, M. Saadi, and K. Dellagi. 2007. Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J. Virol. Methods146(1-2):246-256.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biologicals.2005.07.004","volume":"34","year":"2006","unstructured":"Nagarajan, T., G. S. Reddy, B. Mohana Subramanian, S. Rajalakshmi, D. Thiagarajan, N. Tordo, C. Jallet, and V. A. Srinivasan. 2006. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals34:21-27.","journal-title":"Biologicals"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1073\/pnas.86.10.3833","volume":"86","year":"1989","unstructured":"Orlandi, R., D. H. G\u00fcssow, P. T. Jones, and G. Winter. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. U. S. A.86(10):3833-3837.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","volume":"18","year":"1990","unstructured":"Perrin, P., S. Morgeaux, and P. Sureau. 1990. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. Biologicals18:321-330.","journal-title":"Biologicals"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","volume":"11","year":"2007","unstructured":"Sudarshan, M. K., S. N. Madhusudana, B. J. Mahendra, N. S. Rao, D. H. Ashwathnarayana, S. Abdul Rahman, F. X. Meslin, D. Lobo, K. Ravikumar, and Gangaboraiah. 2007. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int. J. Infect. Dis.11:29-35.","journal-title":"Int. J. Infect. Dis."},{"key":"e_1_3_2_23_2","unstructured":"Statistical methods applied to experiments in agriculture and biology 1989"},{"key":"e_1_3_2_24_2","first-page":"360","year":"1996","unstructured":"Wilber, L. A., and M. F. A. Aubert. 1996. The NIH test for potency, p. 360-368. In F. X. Meslin, M. M. Kaplan, and H. Koprowski (ed.), Laboratory techniques in rabies, 4th ed. WHO, Geneva, Switzerland.","journal-title":"Laboratory techniques in rabies"},{"key":"e_1_3_2_25_2","unstructured":"Potency and stability of various modern rabies vaccines for veterinary use 1988"},{"key":"e_1_3_2_26_2","unstructured":"Rabies 2001"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00204-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00204-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:43:48Z","timestamp":1627591428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00204-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1128\/CVI.00204-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00204-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"2010-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}